Leukotriene receptors as potential therapeutic targets

J Clin Invest. 2018 Jul 2;128(7):2691-2701. doi: 10.1172/JCI97946.

Takehiko Yokomizo ¹, Motonao Nakamura ², Takao Shimizu ³ ⁴

Affiliations

1 Department of Biochemistry, Graduate School of Medicine, Juntendo University, Tokyo, Japan.
2 Department of Life Science, Graduate School of Science, Okayama University of Science, Okayama, Japan.
3 Department of Lipidomics, Faculty of Medicine, University of Tokyo, Tokyo, Japan.
4 Department of Lipid Signaling, National Center for Global Health and Medicine, Tokyo, Japan.

PMID: 29757196 DOI: 10.1172/JCI97946

Abstract

Leukotrienes, a class of arachidonic acid-derived bioactive molecules, are known as mediators of allergic and inflammatory reactions and considered to be important drug targets. Although an inhibitor of leukotriene biosynthesis and antagonists of the cysteinyl Leukotriene Receptor are clinically used for bronchial asthma and allergic rhinitis, these medications were developed before the molecular identification of leukotriene receptors. Numerous studies using cloned leukotriene receptors and genetically engineered mice have unveiled new pathophysiological roles for leukotrienes. This Review covers the recent findings on leukotriene receptors to revisit them as new drug targets.

Name
Email *

	Sorry, but the email address you supplied was invalid.